LBW242 inhibits human plasmacytoma growth and prolongs survival in immune-deficient beige-nude-xid (BNX) mice. (A) Kinetics of myeloma xenograft growth. Mice (n = 8) received LBW242 (35 mg/kg, orally) for 2 weeks daily. A significant delay in tumor growth in LBW242-treated mice was noted compared with vehicle-treated control mice (n = 6; P = .03). Points indicate mean; bars, SE. Inset photographs show the tumors excised from control (vehicle) and LBW242-treated mice. (B) Daily treatment was started on day 1, when tumors were measurable. Mice were treated with LBW242 or with vehicle alone for 2 weeks daily. Survival was evaluated from the first day of treatment until death using the SigmaPlot analysis software.